VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2.